DRUG
Bright Minds Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · CA
$65.16
−4.20%Next report
Analyst consensus
- Next report date
- Dec 22, 2026
- EPS estimate
- -$1.07
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 17, 2026
- EPS actual
- -$0.17
- EPS estimate
- -$1.22
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +46.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $146
- PT range
- $145 – $147
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 22, 2026